Allameh Tabatabai University Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01675804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Department of Clinical Psychology, Allameh Tabatabaei University, Tehran, Iran.

Active Ingredients

Drugs in Phase 3 Trials (1)

methylphenidate (ritalin) (2 trials)

Drugs in Other Trials (1)

losartan (cozaar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Hyperkinesis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2